U.S. Customs and Border Protection · CROSS Database · 1 HTS code referenced
Primary HTS Code
3004.90.9115
$4641.1M monthly imports
Compare All →
Ruling Age
10 years
Data compiled from CBP CROSS Rulings, Census Bureau Trade Data · As of 2026-04-29 · Updates monthly
The tariff classification of Capecitabine Tablets in dosage form, from India
N268551 September 24, 2015 CLA-2-30:OT:RR:NC:2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9115 Martha M. Scott NorthStar Healthcare 3300 Cork Airport, Business Park Kinsale Road, Cork Ireland RE: The tariff classification of Capecitabine Tablets in dosage form, from India Dear Ms. Scott: In your letter dated September 7, 2015, you requested a tariff classification ruling. The subject product, Capecitabine Tablets, imported in 150 mg and 500 mg, is a medicinal preparation containing Capecitabine, an antineoplastic agent, as the active ingredient. It is indicated for the treatment of metastatic breast cancer and colorectal cancer. The applicable subheading for the Capecitabine Tablets in dosage form, will be 3004.90.9115, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Antineoplastic and immunosuppressive medicaments.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at judy.h.lee@cbp.dhs.gov. Sincerely, Gwenn Klein Kirschner Director National Commodity Specialist Division